nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC22A3—Irinotecan—colon cancer	0.355	0.43	CbGbCtD
Amphetamine—SLC22A3—Vincristine—colon cancer	0.311	0.376	CbGbCtD
Amphetamine—CYP2A6—Fluorouracil—colon cancer	0.161	0.195	CbGbCtD
Amphetamine—Sudden death—Irinotecan—colon cancer	0.00452	0.03	CcSEcCtD
Amphetamine—Cardiomyopathy—Fluorouracil—colon cancer	0.00433	0.0287	CcSEcCtD
Amphetamine—Sudden death—Fluorouracil—colon cancer	0.00433	0.0287	CcSEcCtD
Amphetamine—Cardiomyopathy—Capecitabine—colon cancer	0.00303	0.0201	CcSEcCtD
Amphetamine—Sudden death—Capecitabine—colon cancer	0.00303	0.0201	CcSEcCtD
Amphetamine—CARTPT—lymphoid tissue—colon cancer	0.00298	0.135	CbGeAlD
Amphetamine—Speech disorder—Irinotecan—colon cancer	0.00269	0.0179	CcSEcCtD
Amphetamine—Accidental injury—Irinotecan—colon cancer	0.00262	0.0174	CcSEcCtD
Amphetamine—Speech disorder—Fluorouracil—colon cancer	0.00258	0.0171	CcSEcCtD
Amphetamine—Sudden death—Methotrexate—colon cancer	0.00225	0.015	CcSEcCtD
Amphetamine—Euphoric mood—Fluorouracil—colon cancer	0.0019	0.0126	CcSEcCtD
Amphetamine—Injury—Irinotecan—colon cancer	0.00183	0.0121	CcSEcCtD
Amphetamine—Cerebrovascular accident—Irinotecan—colon cancer	0.00171	0.0114	CcSEcCtD
Amphetamine—CARTPT—lymph node—colon cancer	0.00168	0.0761	CbGeAlD
Amphetamine—Blood pressure increased—Capecitabine—colon cancer	0.00155	0.0103	CcSEcCtD
Amphetamine—Irritability—Fluorouracil—colon cancer	0.00154	0.0102	CcSEcCtD
Amphetamine—Erectile dysfunction—Vincristine—colon cancer	0.00137	0.00911	CcSEcCtD
Amphetamine—Photosensitivity reaction—Vincristine—colon cancer	0.00136	0.00903	CcSEcCtD
Amphetamine—Weight decreased—Vincristine—colon cancer	0.00135	0.00895	CcSEcCtD
Amphetamine—Speech disorder—Methotrexate—colon cancer	0.00134	0.0089	CcSEcCtD
Amphetamine—Depression—Vincristine—colon cancer	0.00133	0.0088	CcSEcCtD
Amphetamine—Weight decreased—Irinotecan—colon cancer	0.00131	0.00872	CcSEcCtD
Amphetamine—Acute coronary syndrome—Vincristine—colon cancer	0.00131	0.0087	CcSEcCtD
Amphetamine—Myocardial infarction—Vincristine—colon cancer	0.0013	0.00865	CcSEcCtD
Amphetamine—Acute coronary syndrome—Irinotecan—colon cancer	0.00128	0.00847	CcSEcCtD
Amphetamine—Sweating—Vincristine—colon cancer	0.00127	0.00846	CcSEcCtD
Amphetamine—Photosensitivity reaction—Fluorouracil—colon cancer	0.00127	0.00842	CcSEcCtD
Amphetamine—Myocardial infarction—Irinotecan—colon cancer	0.00127	0.00842	CcSEcCtD
Amphetamine—Sweating—Irinotecan—colon cancer	0.00124	0.00824	CcSEcCtD
Amphetamine—Acute coronary syndrome—Fluorouracil—colon cancer	0.00122	0.00811	CcSEcCtD
Amphetamine—Myocardial infarction—Fluorouracil—colon cancer	0.00122	0.00807	CcSEcCtD
Amphetamine—Libido decreased—Capecitabine—colon cancer	0.00121	0.00805	CcSEcCtD
Amphetamine—Urinary tract infection—Fluorouracil—colon cancer	0.00121	0.008	CcSEcCtD
Amphetamine—Cerebrovascular accident—Capecitabine—colon cancer	0.00115	0.00761	CcSEcCtD
Amphetamine—SLC22A3—embryo—colon cancer	0.00115	0.0519	CbGeAlD
Amphetamine—Disturbance in sexual arousal—Capecitabine—colon cancer	0.00112	0.0074	CcSEcCtD
Amphetamine—Irritability—Capecitabine—colon cancer	0.00107	0.00712	CcSEcCtD
Amphetamine—Mood swings—Capecitabine—colon cancer	0.00107	0.00707	CcSEcCtD
Amphetamine—MAOB—embryo—colon cancer	0.00106	0.0481	CbGeAlD
Amphetamine—Abdominal pain upper—Capecitabine—colon cancer	0.00103	0.00681	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.00101	0.00672	CcSEcCtD
Amphetamine—SLC18A2—digestive system—colon cancer	0.000999	0.0453	CbGeAlD
Amphetamine—Agitation—Vincristine—colon cancer	0.000955	0.00633	CcSEcCtD
Amphetamine—SLC22A3—smooth muscle tissue—colon cancer	0.000901	0.0408	CbGeAlD
Amphetamine—Convulsion—Vincristine—colon cancer	0.0009	0.00597	CcSEcCtD
Amphetamine—Hypertension—Vincristine—colon cancer	0.000897	0.00595	CcSEcCtD
Amphetamine—Photosensitivity reaction—Capecitabine—colon cancer	0.000887	0.00589	CcSEcCtD
Amphetamine—SLC18A2—vagina—colon cancer	0.000882	0.04	CbGeAlD
Amphetamine—Weight decreased—Capecitabine—colon cancer	0.000879	0.00583	CcSEcCtD
Amphetamine—Hypertension—Irinotecan—colon cancer	0.000874	0.0058	CcSEcCtD
Amphetamine—SLC22A3—renal system—colon cancer	0.000868	0.0393	CbGeAlD
Amphetamine—Depression—Capecitabine—colon cancer	0.000864	0.00573	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000859	0.0057	CcSEcCtD
Amphetamine—Acute coronary syndrome—Capecitabine—colon cancer	0.000854	0.00567	CcSEcCtD
Amphetamine—Cerebrovascular accident—Methotrexate—colon cancer	0.000854	0.00567	CcSEcCtD
Amphetamine—Myocardial infarction—Capecitabine—colon cancer	0.000849	0.00564	CcSEcCtD
Amphetamine—Anaphylactic shock—Vincristine—colon cancer	0.000848	0.00563	CcSEcCtD
Amphetamine—Infection—Vincristine—colon cancer	0.000842	0.00559	CcSEcCtD
Amphetamine—Urinary tract infection—Capecitabine—colon cancer	0.000842	0.00559	CcSEcCtD
Amphetamine—Convulsion—Fluorouracil—colon cancer	0.00084	0.00557	CcSEcCtD
Amphetamine—Anaphylactic shock—Irinotecan—colon cancer	0.000826	0.00548	CcSEcCtD
Amphetamine—Chest pain—Fluorouracil—colon cancer	0.000825	0.00547	CcSEcCtD
Amphetamine—Infection—Irinotecan—colon cancer	0.00082	0.00544	CcSEcCtD
Amphetamine—Hyperhidrosis—Vincristine—colon cancer	0.00082	0.00544	CcSEcCtD
Amphetamine—Anorexia—Vincristine—colon cancer	0.000808	0.00536	CcSEcCtD
Amphetamine—MAOB—renal system—colon cancer	0.000803	0.0364	CbGeAlD
Amphetamine—Irritability—Methotrexate—colon cancer	0.000799	0.0053	CcSEcCtD
Amphetamine—Hyperhidrosis—Irinotecan—colon cancer	0.000798	0.0053	CcSEcCtD
Amphetamine—Mood swings—Methotrexate—colon cancer	0.000793	0.00526	CcSEcCtD
Amphetamine—Anaphylactic shock—Fluorouracil—colon cancer	0.000791	0.00525	CcSEcCtD
Amphetamine—CYP2A6—vagina—colon cancer	0.000788	0.0357	CbGeAlD
Amphetamine—Anorexia—Irinotecan—colon cancer	0.000787	0.00522	CcSEcCtD
Amphetamine—Infection—Fluorouracil—colon cancer	0.000786	0.00521	CcSEcCtD
Amphetamine—Tachycardia—Fluorouracil—colon cancer	0.000772	0.00512	CcSEcCtD
Amphetamine—Insomnia—Vincristine—colon cancer	0.000767	0.00509	CcSEcCtD
Amphetamine—Anorexia—Fluorouracil—colon cancer	0.000754	0.005	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000754	0.005	CcSEcCtD
Amphetamine—Insomnia—Irinotecan—colon cancer	0.000747	0.00496	CcSEcCtD
Amphetamine—SLC18A2—liver—colon cancer	0.000744	0.0337	CbGeAlD
Amphetamine—Decreased appetite—Vincristine—colon cancer	0.000737	0.00489	CcSEcCtD
Amphetamine—Dyspnoea—Irinotecan—colon cancer	0.000736	0.00488	CcSEcCtD
Amphetamine—Erythema multiforme—Capecitabine—colon cancer	0.000736	0.00488	CcSEcCtD
Amphetamine—Somnolence—Irinotecan—colon cancer	0.000734	0.00487	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Vincristine—colon cancer	0.000732	0.00486	CcSEcCtD
Amphetamine—Fatigue—Vincristine—colon cancer	0.000731	0.00485	CcSEcCtD
Amphetamine—Dyspepsia—Irinotecan—colon cancer	0.000727	0.00482	CcSEcCtD
Amphetamine—Constipation—Vincristine—colon cancer	0.000725	0.00481	CcSEcCtD
Amphetamine—Decreased appetite—Irinotecan—colon cancer	0.000718	0.00476	CcSEcCtD
Amphetamine—Insomnia—Fluorouracil—colon cancer	0.000715	0.00475	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Irinotecan—colon cancer	0.000713	0.00473	CcSEcCtD
Amphetamine—Fatigue—Irinotecan—colon cancer	0.000712	0.00472	CcSEcCtD
Amphetamine—Constipation—Irinotecan—colon cancer	0.000706	0.00469	CcSEcCtD
Amphetamine—Dyspnoea—Fluorouracil—colon cancer	0.000705	0.00468	CcSEcCtD
Amphetamine—Somnolence—Fluorouracil—colon cancer	0.000703	0.00467	CcSEcCtD
Amphetamine—Dyspepsia—Fluorouracil—colon cancer	0.000696	0.00462	CcSEcCtD
Amphetamine—Gastrointestinal pain—Vincristine—colon cancer	0.000693	0.0046	CcSEcCtD
Amphetamine—SLC6A4—digestive system—colon cancer	0.000693	0.0314	CbGeAlD
Amphetamine—Decreased appetite—Fluorouracil—colon cancer	0.000688	0.00456	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000683	0.00453	CcSEcCtD
Amphetamine—Gastrointestinal pain—Irinotecan—colon cancer	0.000675	0.00448	CcSEcCtD
Amphetamine—Abdominal pain—Vincristine—colon cancer	0.00067	0.00445	CcSEcCtD
Amphetamine—Body temperature increased—Vincristine—colon cancer	0.00067	0.00445	CcSEcCtD
Amphetamine—Erectile dysfunction—Methotrexate—colon cancer	0.000666	0.00442	CcSEcCtD
Amphetamine—CYP2A6—liver—colon cancer	0.000665	0.0301	CbGeAlD
Amphetamine—Photosensitivity reaction—Methotrexate—colon cancer	0.00066	0.00438	CcSEcCtD
Amphetamine—MAOB—digestive system—colon cancer	0.000659	0.0298	CbGeAlD
Amphetamine—Abdominal pain—Irinotecan—colon cancer	0.000653	0.00433	CcSEcCtD
Amphetamine—Body temperature increased—Irinotecan—colon cancer	0.000653	0.00433	CcSEcCtD
Amphetamine—Depression—Methotrexate—colon cancer	0.000643	0.00427	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.00064	0.00424	CcSEcCtD
Amphetamine—Tremor—Capecitabine—colon cancer	0.000634	0.00421	CcSEcCtD
Amphetamine—SLC22A5—renal system—colon cancer	0.000631	0.0286	CbGeAlD
Amphetamine—SLC22A3—vagina—colon cancer	0.000628	0.0285	CbGeAlD
Amphetamine—Urticaria—Fluorouracil—colon cancer	0.000628	0.00417	CcSEcCtD
Amphetamine—Body temperature increased—Fluorouracil—colon cancer	0.000625	0.00415	CcSEcCtD
Amphetamine—Hypersensitivity—Vincristine—colon cancer	0.000625	0.00415	CcSEcCtD
Amphetamine—Sweating—Methotrexate—colon cancer	0.000618	0.0041	CcSEcCtD
Amphetamine—Hypersensitivity—Irinotecan—colon cancer	0.000608	0.00404	CcSEcCtD
Amphetamine—Asthenia—Vincristine—colon cancer	0.000608	0.00404	CcSEcCtD
Amphetamine—Palpitations—Capecitabine—colon cancer	0.000598	0.00397	CcSEcCtD
Amphetamine—Asthenia—Irinotecan—colon cancer	0.000592	0.00393	CcSEcCtD
Amphetamine—Hypertension—Capecitabine—colon cancer	0.000585	0.00388	CcSEcCtD
Amphetamine—Hypersensitivity—Fluorouracil—colon cancer	0.000583	0.00387	CcSEcCtD
Amphetamine—MAOB—vagina—colon cancer	0.000582	0.0263	CbGeAlD
Amphetamine—Diarrhoea—Vincristine—colon cancer	0.00058	0.00385	CcSEcCtD
Amphetamine—Chest pain—Capecitabine—colon cancer	0.000577	0.00383	CcSEcCtD
Amphetamine—Anxiety—Capecitabine—colon cancer	0.000575	0.00381	CcSEcCtD
Amphetamine—SLC18A2—lymph node—colon cancer	0.000571	0.0259	CbGeAlD
Amphetamine—Diarrhoea—Irinotecan—colon cancer	0.000565	0.00375	CcSEcCtD
Amphetamine—Dry mouth—Capecitabine—colon cancer	0.000564	0.00374	CcSEcCtD
Amphetamine—Dizziness—Vincristine—colon cancer	0.000561	0.00372	CcSEcCtD
Amphetamine—Infection—Capecitabine—colon cancer	0.000549	0.00364	CcSEcCtD
Amphetamine—Erythema multiforme—Methotrexate—colon cancer	0.000548	0.00363	CcSEcCtD
Amphetamine—Dizziness—Irinotecan—colon cancer	0.000546	0.00362	CcSEcCtD
Amphetamine—Diarrhoea—Fluorouracil—colon cancer	0.000541	0.00359	CcSEcCtD
Amphetamine—Tachycardia—Capecitabine—colon cancer	0.000539	0.00358	CcSEcCtD
Amphetamine—Vomiting—Vincristine—colon cancer	0.000539	0.00358	CcSEcCtD
Amphetamine—Rash—Vincristine—colon cancer	0.000535	0.00355	CcSEcCtD
Amphetamine—Hyperhidrosis—Capecitabine—colon cancer	0.000534	0.00355	CcSEcCtD
Amphetamine—Dermatitis—Vincristine—colon cancer	0.000534	0.00354	CcSEcCtD
Amphetamine—Headache—Vincristine—colon cancer	0.000531	0.00352	CcSEcCtD
Amphetamine—SLC22A3—liver—colon cancer	0.00053	0.024	CbGeAlD
Amphetamine—Anorexia—Capecitabine—colon cancer	0.000527	0.0035	CcSEcCtD
Amphetamine—Vomiting—Irinotecan—colon cancer	0.000525	0.00348	CcSEcCtD
Amphetamine—Dizziness—Fluorouracil—colon cancer	0.000523	0.00347	CcSEcCtD
Amphetamine—Rash—Irinotecan—colon cancer	0.000521	0.00345	CcSEcCtD
Amphetamine—Dermatitis—Irinotecan—colon cancer	0.00052	0.00345	CcSEcCtD
Amphetamine—SLC22A5—digestive system—colon cancer	0.000517	0.0234	CbGeAlD
Amphetamine—Headache—Irinotecan—colon cancer	0.000517	0.00343	CcSEcCtD
Amphetamine—Nausea—Vincristine—colon cancer	0.000504	0.00334	CcSEcCtD
Amphetamine—Vomiting—Fluorouracil—colon cancer	0.000503	0.00334	CcSEcCtD
Amphetamine—Insomnia—Capecitabine—colon cancer	0.0005	0.00332	CcSEcCtD
Amphetamine—Rash—Fluorouracil—colon cancer	0.000499	0.00331	CcSEcCtD
Amphetamine—Dermatitis—Fluorouracil—colon cancer	0.000498	0.00331	CcSEcCtD
Amphetamine—Headache—Fluorouracil—colon cancer	0.000495	0.00329	CcSEcCtD
Amphetamine—Dyspnoea—Capecitabine—colon cancer	0.000493	0.00327	CcSEcCtD
Amphetamine—MAOB—liver—colon cancer	0.000491	0.0222	CbGeAlD
Amphetamine—Nausea—Irinotecan—colon cancer	0.00049	0.00325	CcSEcCtD
Amphetamine—Dyspepsia—Capecitabine—colon cancer	0.000486	0.00323	CcSEcCtD
Amphetamine—Decreased appetite—Capecitabine—colon cancer	0.00048	0.00319	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Capecitabine—colon cancer	0.000477	0.00317	CcSEcCtD
Amphetamine—Fatigue—Capecitabine—colon cancer	0.000476	0.00316	CcSEcCtD
Amphetamine—Constipation—Capecitabine—colon cancer	0.000473	0.00314	CcSEcCtD
Amphetamine—Nausea—Fluorouracil—colon cancer	0.00047	0.00312	CcSEcCtD
Amphetamine—SLC22A5—vagina—colon cancer	0.000457	0.0207	CbGeAlD
Amphetamine—Gastrointestinal pain—Capecitabine—colon cancer	0.000452	0.003	CcSEcCtD
Amphetamine—Urticaria—Capecitabine—colon cancer	0.000439	0.00291	CcSEcCtD
Amphetamine—Abdominal pain—Capecitabine—colon cancer	0.000437	0.0029	CcSEcCtD
Amphetamine—Body temperature increased—Capecitabine—colon cancer	0.000437	0.0029	CcSEcCtD
Amphetamine—Convulsion—Methotrexate—colon cancer	0.000437	0.0029	CcSEcCtD
Amphetamine—Chest pain—Methotrexate—colon cancer	0.000429	0.00285	CcSEcCtD
Amphetamine—Anaphylactic shock—Methotrexate—colon cancer	0.000411	0.00273	CcSEcCtD
Amphetamine—Infection—Methotrexate—colon cancer	0.000409	0.00271	CcSEcCtD
Amphetamine—Hypersensitivity—Capecitabine—colon cancer	0.000407	0.0027	CcSEcCtD
Amphetamine—CYP2D6—renal system—colon cancer	0.000407	0.0184	CbGeAlD
Amphetamine—SLC22A3—lymph node—colon cancer	0.000407	0.0184	CbGeAlD
Amphetamine—Hyperhidrosis—Methotrexate—colon cancer	0.000398	0.00264	CcSEcCtD
Amphetamine—Asthenia—Capecitabine—colon cancer	0.000397	0.00263	CcSEcCtD
Amphetamine—Anorexia—Methotrexate—colon cancer	0.000392	0.0026	CcSEcCtD
Amphetamine—SLC22A5—liver—colon cancer	0.000386	0.0175	CbGeAlD
Amphetamine—Diarrhoea—Capecitabine—colon cancer	0.000378	0.00251	CcSEcCtD
Amphetamine—MAOB—lymph node—colon cancer	0.000376	0.017	CbGeAlD
Amphetamine—Insomnia—Methotrexate—colon cancer	0.000372	0.00247	CcSEcCtD
Amphetamine—Dyspnoea—Methotrexate—colon cancer	0.000367	0.00243	CcSEcCtD
Amphetamine—Somnolence—Methotrexate—colon cancer	0.000366	0.00243	CcSEcCtD
Amphetamine—Dizziness—Capecitabine—colon cancer	0.000365	0.00242	CcSEcCtD
Amphetamine—Dyspepsia—Methotrexate—colon cancer	0.000362	0.0024	CcSEcCtD
Amphetamine—Decreased appetite—Methotrexate—colon cancer	0.000358	0.00237	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Methotrexate—colon cancer	0.000355	0.00236	CcSEcCtD
Amphetamine—Fatigue—Methotrexate—colon cancer	0.000355	0.00235	CcSEcCtD
Amphetamine—Vomiting—Capecitabine—colon cancer	0.000351	0.00233	CcSEcCtD
Amphetamine—Rash—Capecitabine—colon cancer	0.000348	0.00231	CcSEcCtD
Amphetamine—SLC6A2—lymph node—colon cancer	0.000348	0.0158	CbGeAlD
Amphetamine—Dermatitis—Capecitabine—colon cancer	0.000348	0.00231	CcSEcCtD
Amphetamine—Headache—Capecitabine—colon cancer	0.000346	0.0023	CcSEcCtD
Amphetamine—Gastrointestinal pain—Methotrexate—colon cancer	0.000336	0.00223	CcSEcCtD
Amphetamine—CYP2D6—digestive system—colon cancer	0.000334	0.0151	CbGeAlD
Amphetamine—Nausea—Capecitabine—colon cancer	0.000328	0.00218	CcSEcCtD
Amphetamine—Urticaria—Methotrexate—colon cancer	0.000327	0.00217	CcSEcCtD
Amphetamine—Abdominal pain—Methotrexate—colon cancer	0.000325	0.00216	CcSEcCtD
Amphetamine—Body temperature increased—Methotrexate—colon cancer	0.000325	0.00216	CcSEcCtD
Amphetamine—Hypersensitivity—Methotrexate—colon cancer	0.000303	0.00201	CcSEcCtD
Amphetamine—SLC22A5—lymph node—colon cancer	0.000296	0.0134	CbGeAlD
Amphetamine—Asthenia—Methotrexate—colon cancer	0.000295	0.00196	CcSEcCtD
Amphetamine—Diarrhoea—Methotrexate—colon cancer	0.000282	0.00187	CcSEcCtD
Amphetamine—Dizziness—Methotrexate—colon cancer	0.000272	0.00181	CcSEcCtD
Amphetamine—Vomiting—Methotrexate—colon cancer	0.000262	0.00174	CcSEcCtD
Amphetamine—Rash—Methotrexate—colon cancer	0.000259	0.00172	CcSEcCtD
Amphetamine—Dermatitis—Methotrexate—colon cancer	0.000259	0.00172	CcSEcCtD
Amphetamine—Headache—Methotrexate—colon cancer	0.000258	0.00171	CcSEcCtD
Amphetamine—CYP2D6—liver—colon cancer	0.000249	0.0113	CbGeAlD
Amphetamine—Nausea—Methotrexate—colon cancer	0.000244	0.00162	CcSEcCtD
